Scott, NKidd, JacquieArnet, HDargaville, CGoza, MCrengle, SJones, RKerrison, CMcKree Jansen, R2026-01-072026-01-072025-12-12New Zealand Medical Journal, ISSN: 0028-8446 (Print); 1175-8716 (Online), Pasifika Medical Association Group, 138(1627), 79-89. doi: 10.26635/6965.71860028-84461175-8716http://hdl.handle.net/10292/20450Aotearoa New Zealand has one of the highest bowel cancer rates in the world. Bowel cancer incidence is increasing for Māori (the Indigenous people of Aotearoa), while trending downwards for non-Māori. Over half of Māori who get bowel cancer are diagnosed before the age of 60 years and are more likely than non-Māori to die within 2 years. Pacific people also experience bowel cancer inequities. In 2016, a national bowel screening programme for Aotearoa was announced, with an age range of 60-74 years. However, equity modelling showed that the proposed programme would disproportionately benefit non-Māori and that lowering the screening age for Māori and Pacific peoples to 50 years could achieve equal health gains. Over subsequent years, Māori cancer leaders advocated for policy change to lower the bowel screening age by 10 years for Māori. They used academic publications, presentations, letters, position statements, media stories and meetings with government leaders. Despite this advocacy, in 2020, the Government announced it was not going to lower the bowel screening age for Māori and Pacific peoples. The advocates persevered. They were supported in their efforts by new data that further confirmed the increasing bowel cancer incidence for Māori. In 2022, the Government committed to lowering the bowel cancer screening age to 50 for Māori and Pacific peoples. However, what followed was a tardy, phased rollout in only three regions. A year on, a new government embarked on a politically motivated agenda to reject ethnically targeted policies, with further significant equity changes to the programme announced. This paper summarises the lobbying efforts of cancer leaders and the government response, revealing structural and institutional racism, represented by inaction and active rejection of evidence-based advice. We describe the perseverance required to advocate for equity in the face of structural racism and the cost to Māori lives while inaction and racism persist.Open Access. The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers.4206 Public Health42 Health SciencesHealth ServicesClinical ResearchCancerHealth DisparitiesWomen's HealthMinority HealthCancer11 Medical and Health SciencesGeneral & Internal Medicine32 Biomedical and clinical sciences42 Health sciencesHumansNew ZealandEarly Detection of CancerMiddle AgedAgedColorectal NeoplasmsRacismMaleHealthcare DisparitiesMass ScreeningIncidenceFemaleHumansColorectal NeoplasmsMass ScreeningIncidenceAgedMiddle AgedNew ZealandFemaleMaleHealthcare DisparitiesEarly Detection of CancerRacismHumansNew ZealandEarly Detection of CancerMiddle AgedAgedColorectal NeoplasmsRacismMaleHealthcare DisparitiesMass ScreeningIncidenceFemaleJournal ArticleOpenAccess10.26635/6965.7186